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Short Communication
Adriamycin cardiotoxicity monitoring by radionuclide scan
B.A. Robinson' *, B.M. Colls1 & J.G. Turner2
Departments of 'Medical Oncology and 2Nuclear Medicine, Christchurch Hospital, Christchurch, New Zealand.
Adriamycin (doxorubicin) is a valuable cytotoxic
agent the administration of which is limited by the
development of a cumulative, dose-related
cardiomyopathy (Bristow et al., 1982). It has been
suggested that by limiting the total dose of
adriamycin to 550mg m 2 cardiotoxicity may be
avoided but some patients unexpectedly develop
heart failure after less adriamycin (Bristow et al.,
1982) while others may gain further tumour
response from administration of more adriamycin.
The best assessment of cardiac damage is provided
by endomyocardial biopsy, which demonstrates
focal swelling of sarcoplasmic reticulum and
myofibrillar dropout which progresses as
adriamycin dose cumulates (Billingham et al.,
1978). Because expertise and facilities for
endomyocardial biopsy are not universally
available, methods of monitoring myocardial
function have been explored. Radionuclide cardiac
scanning to determine left ventricular ejection
fraction (LVEF) appears useful (Alexander et al.,
1979; Ritchie et al., 1980), and correlates with
pathological changes (Young et al., 1981). Since
March 1980, all patients at Christchurch Hospital
treated with adriamycin have undergone serial
radionuclide scans to monitor cardiac function. We
have recently reviewed the 56 women who received
adriamycin for metastic breast carcinoma, and
found that it was necessary to monitor all the
patients, not just those with identifiable risk factors
as proposed by Bristow et al. (1982).
All 55 women with metastatic breast carcinoma
who had received at least 200mgm-2 adriamycin,
as well as the only woman who developed heart
failure after less adriamycin, were studied. The
mean age of the 56 women was 54 years (range 30-
79 years). Adriamycin, 1 mgkg-1, and
cyclophosphamide, 10mgkg-1, were given i.v. with
oral prednisone, initially at 1-2 week intervals, and
then every 4-6 weeks as outpatients, until disease
progressed or toxicity supervened. Baseline cardiac
scans were performed in 39 women; all were
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scanned after 50% and 75% of the predicted dose
limit of adriamycin and therafter prior to alternate
doses of adriamycin. Risk factors for premature
development of heart failure with adriamycin (Von
Hoff et al., 1979; Bristow et al., 1982) were present
in 19 women. Sixteen had hypertension, including 3
who had prior cardiac disease, and one who was 77
years old; two had past episodes of cardiac failure,
and one other was >70 years. The predicted dose
limit of adriamycin was 450mgm 2 if any risk
factor was present, and 550mgm-2 for all other
patients.
Radionuclide equilibrium gated blood pool
cardiac scans, using 99Tcm-pertechnitate-labelled red
cells, were performed at rest in the left anterior
oblique projection. Multigated imaging sequences
were collected in 12 frame histogram mode by a
Gamma-11 computer system, over at least 300
cardiac cycles. The left ventricular ejection fraction
(LVEF) was calculated by one observer (JGT)
using a modified fortran Decus HRTIMG
programme. An ejection fraction of <50%
represented significantly subnormal myocardial
function. When LVEF was <50% or when
cardiotoxicity was suspected clinically, the cardiac
scan was repeated, and if LVEF remained <50%,
no more adriamycin was given.
At evaluation, 18 women were still receiving
adriamycin, 2 having exceeded their predicted dose
limit. Disease progression necessitated cessation of
adriamycin in 19 women, 6 of whom had exceeded
the predicted limit (5 had risk factors). Five women
ceased to receive chemotherapy for non-cardiac side
effects, one having exceeded the predicted limit.
The remaining 14 women ceased treatment with
adriamycin because sequential LVEFs became
subnormal, 10 having received less adriamycin than
the predicted limit (Table I). The other 4 of the 14
women continued adriamycin treatment beyond the
predicted limit, until LVEF became subnormal after
530 (age 79 years), 550, 560 and 600 (hypertension,
paroxysmal atrial tachycardia) mgm 2 adriamycin.
This last patient, and 5 others who developed a
premature fall in LVEF (Table I) developed clinical
and radiological signs of heart failure. Only 3 of the
6 women who developed heart failure had
identifiable risk factors. The heart failure was
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Table I Cumulative adriamycin dose in 10 patients with
premature fall in radionuclide left ventricular ejection fraction
(LVEF)
Cumulative Baseline
Age Riskfactor adriamycin Radionuclide Radionuclide
(years) ifpresent (mgm2) LVEF* (%) LVEF(%)
72 Prior heart
failure 147 t40
50 225 52,50 68
40 247 43,48 56
62 Hypertension 357 45,49 65
61 Prior heart
failure 361 t5O 64
50 387 t24
54 471 38
45 488 t42,45
50 521 44,40
62 525 t47 58
*Shows first abnormal LVEF, and result of scan repeated within 1
month, no more adriamycin having been administered.
tIndicates development ofheart failure.
reversed clinically in all 6 women following
conventional medical treatment.
The use of serial cardiac scans enabled
irreversible heart failure due to adriamycin toxicity
to be averted, by allowing cessation of adriamycin
in 10 patients who had not yet reached the
predicted limit of adriamycin. It appeared necessary
to monitor LVEF in all patients because 7/10 had
no risk factors for premature development of
cardiotoxicity. In addition, adriamycin was
administered in excess of the predicted dose limit
when serial LVEFs remained normal without onset
ofirreversible heart failure.
The cardiac scan was misleading in 3 cases where
after 50% of the predicted limit of adriamycin,
LVEFs were 41, 51 and 46%, but repeat values
were 55, 68 and 57% respectively. All 3 women had
no evidence of heart failure and continued to
receive adriamycin with subsequently normal
LVEFs. Thus unexpected LVEF results should be
confirmed by a repeat scan. Although most patients
showed a fall in LVEF with accumulation of
adriamycin, there was unusually high variability,
and many high baseline LVEFs obtained. Previous
studies in this Department (unpublished data)
demonstrated a mean serial variability of absolute
LVEF in repeat studies on different days of 6% for
normals and 3% for patients with coronary heart
disease. Some high baseline LVEFs may have
reflected the stress of advanced malignancy. The
use of 50% as the lower limit of normal for LVEF
in this study was found to be practical, in that no
patient developed heart failure after a higher
LVEF. Those who did develop heart failure had
had subnormal LVEFs, and administration of
adriamycin had been stopped before heart failure
was irreversible.
We conclude that radionuclide scans for LVEF
are a simple outpatient test, useful in the prediction
of early cardiotoxicity due to adriamycin. Patients
with and without risk factors should be monitored.
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